Liposomal
sn-2 DHA inserted phospholipid decreases tumor size of fibrosarcoma INTRODUCTION Liposomes especially the multilamella vesicles (MLV) are known to be phagocyted by macrophages. This was considered to be a problem when designing a drug delivery system. If we take another way of looking at this problem, we could take advantage of this draw back of MLU For instance, by encapsulating a biological response modifier, we may activate macrophages. The sn-2 docosahexaenoic acid (DHA) inserted phospholipids (2-DHA-PL) have been receiving attentions on their boosting effects on functional compounds such as retinoid or hormones without any serious side effect. For this reason, it is expected to enhance therapeutic effects of the encapsulated compound. In this study, we evaluated the antitumor activity of 2-DHA-PL liposome against Meth-A fibrosarcoma both in vitro and in vivo.
MATERIALS AND METHODS

Materials
Meth-A fibrosarcoma cells (RCB 0464) were purchased from Riken cell bank (Ibaraki, Japan) and (Table  1 and Fig. 1, B In this study, we realized that 2-DHA-PL liposomes are not unstable as predicted (data not shown). Growth inhibition of 2-DHA-PL liposomes against Meth-A fibrosarcoma cells and phagocytic enhancement of 2-DHA-PL liposomes on macrophage like J774-1 cells were superior to that of soy PL liposomes. It is often reported that enhance activity of immunocyte such as macrophage relates with antitumor.7) Thought our study, we considered that the decrease in tumor size was attributed to the increase in phagocytic activity of the individual macrophage in addition to the increase in that cell number, and also to a direct suppression against tumor cell growth.
